Desmopressin
Desmopressin is a hormone analogue used in specific water-balance and related conditions. Its effects depend on the formulation and clinical setting.
Prescription medicines
Read the studies →
EXPLORE THE BIOLOGY
Content updated · how dates work
Vasopressin pathways and fluid regulation.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for water balance: the best trial may be small, negative or about a different condition. No doses.
| Peptide | Strongest human evidence in our sources | FDA | Human safety data |
|---|---|---|---|
| FDA-approved medicine (3)Approved for the specific uses on its label, which may not be this goal. | |||
| Desmopressin | Nocturia formulation study (2012) · Human randomized trial Nighttime voiding decreased and the first sleep period lengthened. Clinically important low sodium occurred in some treatment groups. Limitation: Formulation and patient selection matter. This study cannot supply instructions for a different desmopressin product, and fewer bathroom trips must be weighed against hyponatremia risk. Studied: 757 adults in the intention-to-treat population, mostly with excessive nighttime urine production. | FDA-approved | FDA label |
| Terlipressin | CONFIRM (2021) · Human randomized trial Verified hepatorenal-syndrome reversal occurred in 32% versus 17%. At 90 days, deaths occurred in 51% versus 45%; respiratory-disorder deaths occurred in 11% versus 2%. Limitation: Improvement in the specified kidney-function endpoint did not demonstrate a survival advantage. Serious respiratory harms are essential context for the result. Studied: 300 adults with type 1 hepatorenal syndrome, randomized 199 to terlipressin and 101 to placebo. | FDA-approved | FDA label |
| Vasopressin | VASST (2008) · Human randomized trial Mortality at 28 days was 35.4% versus 39.3% (P=0.26). At 90 days it was 43.9% versus 49.6% (P=0.11). Neither overall comparison was statistically significant. Limitation: An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations. Studied: 778 patients with septic shock who were already receiving vasopressors. | FDA-approved | FDA label |
Selected studies, not a systematic review. Approval belongs to a specific product and use. Compare two side by side on the comparison pages.
Desmopressin is a hormone analogue used in specific water-balance and related conditions. Its effects depend on the formulation and clinical setting.
Prescription medicines
Read the studies →Terlipressin is a vasopressin-related medicine used in a specific hepatorenal-syndrome setting. Its kidney-function results must be considered with the risk of serious respiratory complications.
Prescription medicines
Read the studies →Arginine vasopressin is a nine-residue hormone involved in water balance and vascular tone. VASST compared vasopressin with norepinephrine in septic shock.
Prescription medicines
Read the studies →See something wrong on this page? Report a mistake · Corrections